May 13, 2024
New agreement with Quallent expands biosimilar access
May 02, 2024
Improving Access to Clinical Trials
May 01, 2024
FDA Approves Additional Formulation of Our Biosimilar
April 16, 2024
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline.
April 06, 2024
Results announced from EMPACT-MI phase III trial
March 19, 2024
New FDA approval for the treatment of GPP
March 12, 2024
Update on sNDA for fibrosing ILD in children and adolescents
March 07, 2024
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month
February 26, 2024
Top-line Phase II Data for treatment of MASH
November 20, 2023
National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)
November 10, 2023
Investigational Compound Granted FDA Orphan Drug Designation
November 06, 2023